Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy - Full Text View

Sponsor:	Dresden University of Technology
Information provided by (Responsible Party):	Dresden University of Technology
ClinicalTrials.gov Identifier:	NCT00324675

Purpose

Objective:

To evaluate how rosiglitazone does influence the renal plasma flow, the glomerular filtration rate and the degree of proteinuria in type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy.

Background:

Diabetic nephropathy is a world wide public health concern of increasing proportions. It has become the most common single cause of end-stage renal disease in the United States and in Europe. Previous studies have already found agents modifying the renin-angiotensin-system (ACE inhibitors and angiotensin receptor blocker) to retard diabetic nephropathy. These agents are likely to exert multiple effects in the kidney. One of them appear to be their known ability to improve endothelial function and to change renal glomerular hemodynamics.

In a previous study we demonstrated an improvement of renal endothelial dysfunction in type 2 diabetic patients without end organ damage after treatment with rosiglitazone. In that study, rosiglitazone significantly reduced glomerular hyperfiltration. This was associated with a reduction of urinary albumin excretion. The observed effects are potentially important in the context of renal protection, provided that a similar beneficial effect of rosiglitazone is demonstrable in overt diabetic nephropathy (renal insufficiency, hypertension, proteinuria).

Hypothesis Rosiglitazone decreases proteinuria and improves renal hemodynamic function in patients with chronic renal insufficiency due to overt diabetic nephropathy.

Condition	Intervention
Type 2 Diabetes Overt Diabetic Nephropathy	Drug: Rosiglitazone Drug: Placebo

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy

Resource links provided by NLM:

Genetics Home Reference related topics: 6q24-related transient neonatal diabetes mellitus

MedlinePlus related topics: Diabetes Diabetes Type 2 Diabetic Kidney Problems

Drug Information available for: Rosiglitazone Rosiglitazone Maleate

U.S. FDA Resources

Further study details as provided by Dresden University of Technology:

Primary Outcome Measures:

Proteinuria [ Time Frame: at baseline and after 6 and 12 mo of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Renal Hemodynamic [ Time Frame: at baseline and after 6 and 12 mo of tretament ] [ Designated as safety issue: No ]
Renal Function [ Time Frame: at abseline and after 6 and 12 mo ] [ Designated as safety issue: Yes ]
Adverse Event [ Time Frame: every month or at occurence ] [ Designated as safety issue: Yes ]
HbA1c [ Time Frame: at baseline and after 6 and 12 mo ] [ Designated as safety issue: Yes ]

Enrollment:	28
Study Start Date:	August 2006
Study Completion Date:	December 2010
Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Rosiglitazone	Drug: Rosiglitazone 4 mg tablets, bid, 12 months
Placebo Comparator: placebo	Drug: Placebo 2 tablets per day

Eligibility

Ages Eligible for Study:	40 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

type 2 diabetes mellitus -age between 40 and 75 years -well controlled HbA1c (< 7.5%) -chronic renal failure (creatinin clearance between 70 and 30 mL/(min x 1.73 m²) according to the Cockroft equation) -proteinuria > 300 mg / 24 hours

Exclusion Criteria:

type 1 diabetes -poorly controlled type 2 diabetes (HbA1c > 7.5%) or unstable blood glucose during the day (capillary blood glucose self monitoring) -elevation of ALT, AST or GGT more than 2.5 fold the upper normal value -CHF (more than grade 1 of NYHA) -uncontrolled hypertension -malignant tumorous disorder -hyper- or hypothyroidism -pregnant women -nursing women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00324675

Locations

Germany
University hospital Dresden
Dresden, Germany, 01307

Sponsors and Collaborators

Dresden University of Technology

Investigators

Principal Investigator:

Frank Pistrosch, M.D.

Nephrology, Department of Medicine, University hospital Dresden

More Information

No publications provided

Responsible Party:	Dresden University of Technology
ClinicalTrials.gov Identifier:	NCT00324675 History of Changes
Other Study ID Numbers:	DN 2
Study First Received:	May 9, 2006
Results First Received:	September 15, 2011
Last Updated:	October 27, 2011
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Dresden University of Technology:

type 2 diabetes,
glomerular filtration rate,
renal plasma flow,

endothelial dysfunction,
proteinuria,
diabetic nephropathy

Additional relevant MeSH terms:

Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Kidney Diseases
Proteinuria
Renal Insufficiency
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

Urologic Diseases
Diabetes Complications
Urination Disorders
Urological Manifestations
Signs and Symptoms
Rosiglitazone
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2012